Cargando…
Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
Background: Familial hypercholesterolemia (FH) is a highly prevalent disorder and a risk factor for early coronary artery disease. The objective of this registry was to document the clinical characteristics of patients with definite FH in Germany and to document lipid profiles, lipid-lowering therap...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267207/ https://www.ncbi.nlm.nih.gov/pubmed/35807095 http://dx.doi.org/10.3390/jcm11133810 |
_version_ | 1784743661856096256 |
---|---|
author | Gitt, Anselm K. Laufs, Ulrich März, Winfried Paar, W. Dieter Bramlage, Peter Marx, Nikolaus Parhofer, Klaus G. |
author_facet | Gitt, Anselm K. Laufs, Ulrich März, Winfried Paar, W. Dieter Bramlage, Peter Marx, Nikolaus Parhofer, Klaus G. |
author_sort | Gitt, Anselm K. |
collection | PubMed |
description | Background: Familial hypercholesterolemia (FH) is a highly prevalent disorder and a risk factor for early coronary artery disease. The objective of this registry was to document the clinical characteristics of patients with definite FH in Germany and to document lipid profiles, lipid-lowering therapy, and lipid target achievement during longitudinal follow-up. Methods: HYDRA-FH was a national, prospective, multicenter, non-interventional registry conducted in 35 centers in Germany. Consecutive adult patients with definite FH were included (n = 241). Results: In the cross-sectional analysis (n = 233), lipid-lowering therapy involved statins (82.0%), ezetimibe (31.8%), and PCSK9 antibodies (18.5%); 11.2% of patients were receiving no lipid-lowering drugs. Median lipid levels were: low-density lipoprotein cholesterol (LDL-C) 134 mg/dL (3.5 mmol/L), high-density lipoprotein cholesterol (HDL-C) 48 mg/dL (1.2 mmol/L), triglycerides 160 mg/dL (1.9 mmol/L), total cholesterol 211 mg/dL (5.5 mmol/L). Values were above the normal threshold (150 mg/dL) for LDL-C in 72.9%, total cholesterol in 29.7%, and triglycerides in 45.0% of patients. After the 12-month follow-up (n = 145), only 17.2% had LDL-C < 70 mg/dL, and 20.7% had either LDL-C < 70 mg/dL or a reduction of ≥50% versus baseline. Conclusion: This study provides insight into the clinical characteristics and current treatment status of patients with FH in Germany. Many patients with FH do not achieve recommended lipid levels. |
format | Online Article Text |
id | pubmed-9267207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92672072022-07-09 Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia Gitt, Anselm K. Laufs, Ulrich März, Winfried Paar, W. Dieter Bramlage, Peter Marx, Nikolaus Parhofer, Klaus G. J Clin Med Article Background: Familial hypercholesterolemia (FH) is a highly prevalent disorder and a risk factor for early coronary artery disease. The objective of this registry was to document the clinical characteristics of patients with definite FH in Germany and to document lipid profiles, lipid-lowering therapy, and lipid target achievement during longitudinal follow-up. Methods: HYDRA-FH was a national, prospective, multicenter, non-interventional registry conducted in 35 centers in Germany. Consecutive adult patients with definite FH were included (n = 241). Results: In the cross-sectional analysis (n = 233), lipid-lowering therapy involved statins (82.0%), ezetimibe (31.8%), and PCSK9 antibodies (18.5%); 11.2% of patients were receiving no lipid-lowering drugs. Median lipid levels were: low-density lipoprotein cholesterol (LDL-C) 134 mg/dL (3.5 mmol/L), high-density lipoprotein cholesterol (HDL-C) 48 mg/dL (1.2 mmol/L), triglycerides 160 mg/dL (1.9 mmol/L), total cholesterol 211 mg/dL (5.5 mmol/L). Values were above the normal threshold (150 mg/dL) for LDL-C in 72.9%, total cholesterol in 29.7%, and triglycerides in 45.0% of patients. After the 12-month follow-up (n = 145), only 17.2% had LDL-C < 70 mg/dL, and 20.7% had either LDL-C < 70 mg/dL or a reduction of ≥50% versus baseline. Conclusion: This study provides insight into the clinical characteristics and current treatment status of patients with FH in Germany. Many patients with FH do not achieve recommended lipid levels. MDPI 2022-06-30 /pmc/articles/PMC9267207/ /pubmed/35807095 http://dx.doi.org/10.3390/jcm11133810 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gitt, Anselm K. Laufs, Ulrich März, Winfried Paar, W. Dieter Bramlage, Peter Marx, Nikolaus Parhofer, Klaus G. Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia |
title | Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia |
title_full | Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia |
title_fullStr | Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia |
title_full_unstemmed | Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia |
title_short | Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia |
title_sort | hypercholesterolemia diagnosis, treatment patterns, and 12-month target achievement in clinical practice in germany in patients with familial hypercholesterolemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267207/ https://www.ncbi.nlm.nih.gov/pubmed/35807095 http://dx.doi.org/10.3390/jcm11133810 |
work_keys_str_mv | AT gittanselmk hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia AT laufsulrich hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia AT marzwinfried hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia AT paarwdieter hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia AT bramlagepeter hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia AT marxnikolaus hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia AT parhoferklausg hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia |